In the SURMOUNT 1 trial, tirzepatide at doses of 5 mg, 10 mg and 15 mg were evaluated against placebo, with pooled tirzepatide groups resulting in significant decreases in total cholesterol, LDL-C, VLDL-C, FFA, and triglycerides and an increase in HDL-C at week 72 of follow-up [35]
Income disparities are similar, with 44.6% of adults in households earning under $15,000 diagnosed as obese
Muscle preservation during GLP-1 or medical weight-loss treatment depends heavily on protein intake, resistance training, adequate nutrition, dose management, sleep, hormones, and medical monitoring
Syringes are inexpensive compared to the peptide
[15] Earlier reviews found some case reports during drug development and post-marketing surveillance